The Vanguard Group, Inc. has recently announced that it has increased stake in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) by 2.44%. After grabbing 6.77 million shares, the institutional investor is now in possession of 0.16 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 6.35% having worth around $97.72 million. Moreover, Dimensional Fund Advisors LP increased its share by 87464.0 to have a control over 2.56 million shares. And Geode Capital Management LLC raised its holdings to 0.16 million shares by acquiring 2.09 million shares or 1.96% of the stake.
Catalyst Pharmaceuticals Inc (CPRX) concluded trading on 12/21/23 at a closing price of $16.07, with 2.52 million shares of worth about $40.53 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 22.21% during that period and on Thursday the price saw a gain of about 12.38%. Currently the company’s common shares owned by public are about 105.26M shares, out of which, 91.49M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 5 analysts are covering the CPRX stock and their offered price forecasts bring an average price target of $26.20. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $30.00 and could fall to a lowest price of $24.00. The stock’s current price level is 38.66% above of average price target set by the analysts, while a rise to estimated low would result in gain of 33.04% for the stock. However, touching the estimated high of $30.00 would mean a gain of 46.43% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 54 times over the past 12 months. They bought 1,014,163 shares in 31 of the transactions. In 23 selling transactions, insiders dumped 350,952 shares.
iShares Core S&P Small Cap ETF, SPDR S&P Biotech ETF, and Vanguard Total Stock Market ETF are the top 3 mutual funds which are holding stakes in Catalyst Pharmaceuticals Inc iShares Core S&P Small Cap ETF is currently holding 6.71 million shares of worth totaling $96.83 million. The company recently came buying 3564.0 shares which brought its stake up to 6.29% of the company’s outstanding shares. SPDR S&P Biotech ETF bought 20910.0 shares, after which its hold over company’s outstanding shares expand to 4.21%, leaving 4.49 million shares with the mutual fund that have a worth of about $64.74 million. Vanguard Total Stock Market ETF, after buying 3.14 million shares, have now control over 2.94% of the stake in the company. It holds 7873.0 shares of worth $45.25 million.
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) started trading at $14.96, above $0.66 from concluding price of the previous day. However, the stock later moved at a day high price of 16.31, or with a gain of 12.38%. Stock saw a price change of 10.90% in past 5 days and over the past one month there was a price change of 16.96%. Year-to-date (YTD), CPRX shares are showing a performance of -13.60% which decreased to -13.60% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $11.09 but also hit the highest price of $22.11 during that period. The average intraday trading volume for Catalyst Pharmaceuticals Inc shares is 1.22 million. The stock is currently trading 12.97% above its 20-day simple moving average (SMA20), while that difference is up 19.29% for SMA50 and it goes to 15.64% higher than SMA200.
The Vanguard Group, Inc. acquired 6.77 million shares of Catalyst Pharmaceuticals Inc having value of about $97.72 million. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 0.16 million shares in the company valued at close to $2589343.03, or have control over 2.44% stake in the company. Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) currently have 105.26M outstanding shares and institutions hold larger chunk of about 69.67% of that. Holding of mutual funds in the company is about 27.71% while other institutional holders and individual stake holders have control over 42.19% and 14.44% of the stake respectively.
The stock has a current market capitalization of $1.71B and its 3Y-monthly beta is at 0.99. PE ratio of stock for trailing 12 months is 30.48, while it has posted earnings per share of $0.53 in the same period. It has Quick Ratio of 3.17 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CPRX, volatility over the week remained 5.34% while standing at 4.00% over the month.
Analysts are in expectations that Catalyst Pharmaceuticals Inc (CPRX) stock would likely to be making an EPS of $0.28 in the current quarter, while forecast for next quarter EPS is $0.26 and it is $1.24 for next year. For the current quarter EPS, analysts have given the company a lowest target $0.23 which is $0.32 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $0.22 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -26.13% while it is estimated to increase by 124.28% in next year.
Analysts at 5 brokerage firms have issued recommendations for the Catalyst Pharmaceuticals Inc (CPRX)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.00. Out of those 5 Wall Street analysts, 5 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on December 21, 2023 offering an Outperform rating for the stock and assigned a target price of $30 to it.
